At Midi Health, starting GLP-1 care is not the same transaction as buying medication. The documented pathway begins with a questionnaire and virtual consultation, moves through a clinician’s prescribing decision, and then branches into pharmacy fulfillment and follow-up. Visits and medicines have separate prices. For someone comparing services, the central question is therefore not simply whether Midi offers GLP-1s, but how clearly each handoff is defined before treatment begins.
Midi presents itself as a virtual healthcare clinic for women, with weight management alongside its broader women’s-health focus. Its public documentation describes branded GLP-1 prescriptions, compounded GLP-1 and GLP-1/GIP offerings, and ongoing clinical appointments. This review examines those arrangements using pages consulted October 19, 2026. The documents explain much of the intended care journey, but leave unresolved differences about state availability and Medicare access, as well as practical questions about specific formulations, delivery timing, and between-visit support.
At a glance
- Initial appointment
- The first virtual visit lasts about 30 minutes; the published self-pay price is $250.
- Follow-up
- Midi advertises 15-minute returning visits, priced at $150 for self-pay patients.
- Compounded medication price
- Compounded GLP-1 and GLP-1/GIP medication starts at $164 per four-week supply, depending on medication, format, and dose; shipping and supplies are included, but visits are separate.Sources: [5]
- Clinical responsibility
- Midi’s terms distinguish the platform operator from the medical groups delivering healthcare and identify Precision Compounding Pharmacy as a prescription-fulfillment partner.Sources: [12]
Start by establishing who is providing care
Midi’s consumer-facing description is a virtual healthcare clinic for women. It says its clinicians are board-certified and trained in women’s health, although this review did not independently verify individual credentials. Its contractual structure is more specific: Midi Health, Inc. and its subsidiaries operate the platform, while the terms say Midi itself is not a healthcare provider and that using the service does not create a provider-patient relationship with Midi.
The terms identify four medical groups through which care may be available: Integrative Women’s Care PC, IWC Medical Group, P.A., IWC Medical Group KS, P.A., and Robert G. Aptekar, M.D., P.C. Those groups employ or contract with physicians, nurses, allied health professionals, and other professionals. Consequently, a reference to a Midi clinician should not automatically be read as a promise that every appointment is with a physician.
This division matters when requesting records, clarifying a prescription, or raising a clinical concern. Before booking, ask which medical group and clinician will be responsible for your care and which contact channel reaches that team rather than administrative support. Our guide to clinicians and telehealth platforms explains why the branding on a website and the entity delivering treatment may differ without being interchangeable.
Check access before completing the clinical intake
Midi’s general eligibility terms require users to be at least 18, or the age of majority in their jurisdiction if higher, and located in a state where the service operates. The weight-management page advertises availability in all 50 states and self-pay visits. However, a GLP-1-specific article says the offering is not available in all 50 states. These statements do not establish which formulation can be prescribed and dispensed at a particular address.
Insurance verification begins during registration, when Midi requests a photograph of the insurance card and says its system identifies whether the patient is in or out of network. Out-of-network patients can choose a self-pay appointment. Midi says it participates with most major insurers, but deductibles, coinsurance, and copayments may still apply. Acceptance of insurance for the appointment does not establish coverage for the medicine subsequently prescribed.
Public-insurance access needs extra clarification. The pricing page welcomes Medicare beneficiaries as self-pay patients but says they cannot submit claims for Midi visits, medicines, or associated services. A separate article updated in December 2024 says Medicare patients cannot be treated even through self-pay. Both documents exclude Medicaid and Medi-Cal patients. Medicare beneficiaries should resolve that contradiction directly before booking, rather than assume either page settles their access.
What the first appointment is meant to accomplish
Before the appointment, Midi’s questionnaire gathers health and weight history, current medicines, previous treatments, risk factors, and goals. The advertised first virtual visit runs about 30 minutes. During it, the clinician reviews history, symptoms, prior treatment, and goals, then recommends a personalized care plan and follow-up. This is a clinical assessment rather than a documented guarantee of access to a particular drug, route, or advertised starting price.
The terms make prescribing conditional on completing a consultation, the provider determining that the product is appropriate, and issuance of a prescription. The program also describes targeted laboratory work, such as blood sugar or cholesterol testing, to guide metabolic care. It does not establish a uniform laboratory panel for everyone, a complete set of exclusion criteria, or a publicly documented BMI threshold that independently determines eligibility.
Preparation is most useful when it supports that assessment rather than aims to secure a predetermined prescription. NIDDK advises discussing medicines, supplements, allergies, and pregnancy plans with the clinician. Bring questions about which tests are necessary, who orders them, where results will be reviewed, and whether testing adds a separate charge. Our first-consultation preparation guide offers a framework for organizing those questions without treating general eligibility information as an individual medical decision.
The prescription can lead to different products and routes
Midi documents both branded GLP-1 prescribing and compounded GLP-1 or GLP-1/GIP prescriptions. Its compounded-product page describes self-injection and oral drops, with the drops placed under the tongue. These are sublingual drops, not tablets swallowed whole. The reviewed material does not unambiguously identify the active ingredient in every offering labeled GLP-1 or GLP-1/GIP, so educational references to particular drugs should not be used to fill in the prescription details.
That makes the product discussion a meaningful part of the consultation. Ask for the exact active ingredient, formulation, route, dispensing pharmacy, and written administration instructions for the proposed prescription. A convenient route or familiar ingredient name does not establish that a preparation has the same evidence as another product. Our formulation-check guide explains how to separate those questions rather than treating all products carrying a GLP-1 label as equivalent.
Midi acknowledges that compounded medicines are not FDA approved. FDA explains that they do not undergo its premarket review for safety, effectiveness, and quality, and recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug, with a prescription and state-licensed pharmacy. Nonapproval alone does not establish clinical inequivalence. Equally, approval of a specific branded product does not extend to Midi as a service or to a different compounded preparation.
Understand the bill at each handoff
Midi advertises no membership fees, but that does not make the care pathway a single bundled purchase. The published self-pay appointment prices are $250 for the initial 30-minute visit and $150 for a returning 15-minute visit. Medication is explicitly priced separately. Midi also says HSA or FSA funds can pay for visits and services; that statement should not be expanded into an individualized tax conclusion or a promise that every related expense qualifies.
The compounded medication offer starts at $164 per four-week supply, depending on medication, format, and dose, including shipping and supplies. Four weeks is not a calendar month, and the starting price does not establish the cost of every preparation or later prescription. A separate “microdosing” offer advertises weekly doses starting at $34 for eligible patients when clinically appropriate. That is not an all-inclusive care price, nor a basis for inferring equivalent benefits across treatment approaches.
For branded GLP-1s, Midi says prescriptions go to the patient’s pharmacy of choice, with cost dependent on the drug and insurance. The documentation does not provide one total combining visits, medicine, and laboratory work for a defined treatment period. Before proceeding, obtain a product-specific estimate and ask when each charge is collected. The absence of a membership fee does not establish a fixed appointment schedule, a medication price lock, or freedom from every product-specific recurring arrangement.
| Service or product | Published amount | What the amount does not establish |
|---|---|---|
| Initial self-pay visit | $250; approximately 30 minutes | Medication or laboratory costs are not established as included. |
| Returning self-pay visit | $150; approximately 15 minutes | No uniform follow-up frequency is stated. |
| Compounded GLP-1 or GLP-1/GIP | Starts at $164 per four-week supply; shipping and supplies included | Price varies by medication, format, and dose; visits are separate. |
| Conditional microdosing offer | Weekly doses start at $34 for eligible patients | Not a complete treatment price; requires clinical appropriateness. |
| Branded GLP-1 prescription | Depends on drug cost and insurance | Visit coverage does not establish pharmacy coverage. |
From prescription to dispensing and delivery
Midi’s terms identify Precision Compounding Pharmacy as a prescription-fulfillment partner. Elsewhere, Midi describes its partner compounding pharmacies as licensed and “503A-accredited”; that is the provider’s wording, not an independently verified accreditation finding here. Identifying a fulfillment pharmacy does not, by itself, establish who compounded every preparation. Ask which pharmacy will dispense the actual order and, where relevant, which facility prepared it, rather than relying solely on a general partner description.
The terms also allow certain prescriptions to be sent to another selected pharmacy. In that case, the patient pays that pharmacy directly and is responsible for pickup or otherwise obtaining the medicine. That general option should not be interpreted as a guarantee that every customized formulation is transferable or available elsewhere. The branded-drug page expressly supports a pharmacy of choice, making it important to clarify which fulfillment pathway applies to the proposed product.
Shipping is included in the advertised compounded starting price, and Midi says orders ship discreetly. The reviewed documentation does not establish guaranteed clinical-review, dispatch, or arrival times, or detailed cold-chain conditions. Store terms require a physical U.S. address and describe delivery dates as estimates. FDA advises not using an injectable GLP-1 that arrives warm or with insufficient refrigeration and contacting the provider or dispensing pharmacy. Our pharmacy-handoff guide helps identify who should answer fulfillment questions before an order ships.
Follow-up is documented, but between-visit access is less clear
Midi says a care plan may include GLP-1s, laboratory orders, and guidance, with 15-minute follow-up visits to track progress and make adjustments. It also says clinicians help patients manage side effects. Those are meaningful service descriptions, but the public material reviewed does not set a standard follow-up interval or guaranteed response time. A prospective patient should ask how the next appointment is scheduled and what happens if a concern arises before it.
A Midi article says patients prescribed personalized GLP-1 medicines are also supplied ondansetron tablets for significant nausea or vomiting. The passage does not establish whether that medicine is included without an additional charge in every treatment arrangement. It is best treated as a specific question for the prescribing team, not an automatic benefit or a substitute for clinical evaluation. FDA has also reported compounded-medication measurement and administration errors; unclear instructions should be resolved with the prescriber or pharmacist.
Published support hours of Monday through Friday, 9 a.m. to 5 p.m. Eastern, accompany accessibility and ordering help through store@joinmidi.com and 1-888-731-8994. They do not establish continuous clinical coverage. Ask separately about clinical messages, urgent concerns, and any charges for additional encounters. Midi’s terms also warn that not every prescription uses child-resistant packaging, making the actual container and pharmacy-provided storage instructions another practical part of the handoff.
Separate clinical continuation from recurring purchases
Although Midi advertises no membership fee, its terms permit automatically renewing subscriptions for certain supplements and certain prescription products called CustomRX. This does not prove that every GLP-1 prescription is sold on subscription. For an applicable subscription, charges continue until cancellation, and the cancellation deadline is specified in the subscription’s own terms. Patients should request those product-specific terms before agreeing, including whether payment is recurring and how renewal relates to clinical reassessment.
The general terms allow cancellation through the online account, support@joinmidi.com, or 1-888-731-8994. They do not ordinarily offer refunds for partially used subscription periods, except at Midi’s discretion or where required by law. The first renewal may be charged early; subsequent shipments may be charged and dispatched up to two days early for operational reasons. Cancellation therefore concerns future charges and should not be mistaken for a promise to refund an order already processed.
For CustomRX subscriptions, Midi says it will not bill or ship unless the prescription is active and refill-eligible, the product remains eligible and legally available in the state, and a pharmacy can dispense it. Those checks are distinct from a clinical follow-up appointment. Likewise, Midi’s Daily GLP-1 Support is a nutritional supplement, explicitly not a weight-loss product or something intended to change GLP-1 efficacy; its subscription should not be confused with the medication or clinical-care arrangement.
Questions & answers
Does paying for a Midi appointment guarantee a GLP-1 prescription?
No. Midi’s terms require a consultation, a clinician’s determination that the product is appropriate, and a valid prescription. The initial visit is an assessment and care-planning appointment, not a guaranteed medication purchase. Ask what the visit charge covers if the clinician recommends another approach, and do not assume that paying for a visit secures a particular formulation or price.
Is the $164 offer the full cost of starting treatment?
No. It is a starting price for a four-week supply of compounded GLP-1 or GLP-1/GIP medication, varying by medicine, format, and dose. Shipping and supplies are included, but consultations are billed separately. The initial self-pay visit is $250. Laboratory costs and the exact prescribed product need clarification; the documents do not establish one complete starting-treatment package.
Can I use my usual pharmacy?
Midi explicitly says branded GLP-1 prescriptions can go to the pharmacy of your choice. Its terms also describe sending certain prescriptions to an outside pharmacy, where you pay directly and arrange pickup or delivery. Confirm availability for the exact prescription first: these provisions do not establish that every compounded formulation can be filled through any pharmacy you select.
Can Medicare beneficiaries book self-pay care?
The consulted pages conflict. Midi’s pricing page welcomes Medicare beneficiaries as self-pay patients while prohibiting claims for related visits, medicines, and services. A separate article updated in December 2024 says Medicare patients cannot receive treatment even through self-pay. Confirm the policy for your proposed service before booking. The documents also state that Midi does not accept Medicaid or Medi-Cal patients.
Does Midi offer oral GLP-1 treatment?
Midi describes compounded oral drops placed under the tongue, alongside a self-injection option. Those drops should not be confused with swallowed tablets. Ask the clinician to identify the exact ingredient, preparation, and evidence relevant to that route. The documentation reviewed does not establish that the drops share the approval status or clinical results of another oral or injectable product.
How do I stop a recurring Midi product order?
For products on an applicable subscription, the terms permit cancellation in the online account, by emailing support@joinmidi.com, or by calling 1-888-731-8994. Cancel before the deadline in your subscription terms to avoid the next charge, accounting for possible early processing. Cancellation does not ordinarily produce a refund for a partially used period, and these subscription rules should not automatically be applied to every GLP-1 prescription.
Our assessment
Midi documents a recognizable care pathway: advance intake, a substantial initial consultation, conditional prescribing, pharmacy fulfillment, and shorter follow-up visits. Its separate visit and medication pricing is useful, and the branded-pharmacy option gives patients a clearly described alternative fulfillment route. The main limitations concern the connections between those steps: exact compounded formulations, state-specific availability, laboratory charges, delivery expectations, and between-visit clinical access require confirmation. The Medicare contradiction also deserves resolution before enrollment. A practical next step is to request a written, product-specific outline naming the treating group, dispensing pharmacy, expected charges, follow-up arrangements, and any recurring-order terms. That would make the documented service easier to evaluate without assuming guaranteed prescribing, uniform access, or outcomes.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Midi Health — products/daily glp 1 support ↗
- Midi Health — post/hrt cost ↗
- Midi Health — weight management ↗
- Midi Health — pricing insurance ↗
- Midi Health — post/midi glp 1 programs ↗
- Midi Health — store/weight loss ↗
- Midi Health — glp1 pricing ↗
- Midi Health — post/oral semaglutide weight loss ↗
- Midi Health — official website ↗
- Midi Health — legals/terms and conditions ↗